Quick Takeaways
- Commodore Capital LP filed SCHEDULE 13G/A for Definium Therapeutics, Inc. Common Shares, no par value per share.
- Disclosed ownership: 7.2%.
- Date of event: 31 Dec 2025.
Commodore Capital LP - 31 Dec 2025 SCHEDULE 13G/A Report for Definium Therapeutics, Inc. Common Shares, no par value per share
- Filing Manager
- Commodore Capital LP
- Reporting Manager
- Commodore Capital LP
- Shares outstanding
- 103,177,431 shares
- Disclosed Ownership
- 7,428,775 shares
- Ownership
- 7.2%
- Form type
- SCHEDULE 13G/A
- Filing time
- 17 Feb 2026, 16:21:24 UTC
- Date of event
- 31 Dec 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Commodore Capital LP disclosed 7.2% ownership in Definium Therapeutics, Inc. Common Shares, no par value per share on 31 Dec 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 17 Feb 2026, 16:21.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (4)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Commodore Capital LP | 7.2% | 7,428,775 | 0 | 7,428,775 | Michael Kramarz | Managing Partner | |
| Commodore Capital Master LP | 7.2% | 7,428,775 | 0 | 7,428,775 | Michael Kramarz | Authorized Signatory | |
| Robert Egen Atkinson | 7.2% | 7,428,775 | 0 | 7,428,775 | Robert Egen Atkinson | Authorized Signatory | |
| Michael Kramarz | 7.2% | 7,428,775 | 0 | 7,428,775 | Michael Kramarz | Authorized Signatory |